92Bio

Executive Summary

92Bio is a private biotechnology company headquartered in Cambridge, MA, focused on developing next-generation multispecific T-cell engagers (TCEs) for cancer treatment. Founded in 2020, the company leverages advanced antibody engineering and novel immune cell subsets, particularly γδ T-cells, to design fit-for-purpose therapeutics aimed at improving outcomes in both solid and hematologic tumors. 92Bio's approach differentiates from conventional TCEs by targeting alternative T-cell populations, potentially offering improved safety and efficacy profiles, especially in solid tumors where traditional TCEs have faced challenges. The company operates in the competitive biologics space, with a strong emphasis on innovation in multispecific antibody design. As a private entity, 92Bio has not disclosed its funding or valuation, but its technological platform and focus on γδ T-cells position it as a potential disruptor in the immuno-oncology field. The company's progress remains early-stage, with no disclosed pipeline details, suggesting preclinical or early clinical development. Key upcoming catalysts include potential IND filings for lead programs, initial clinical data readouts, and strategic partnerships to advance its pipeline.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead γδ T-Cell Engager Program60% success
• Q4 2026Preclinical Data Presentation at Major Conference75% success
• Q2 2027Series A or B Financing Round50% success